NCT05488613View on ClinicalTrials.gov

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

CompletedOBSERVATIONAL
Enrollment

81

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

January 26, 2021

Study Completion Date

January 26, 2021

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Midostaurin

Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.

Trial Locations (1)

Unknown

Novartis Investigative Site, Helsinki

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY